Loading
A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Jiangsu Healthy Life Innovation Medical Technology Co., Ltd, now recruiting.
Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer is a phase 3 interventional study registered as NCT05653453 by Jiangsu Healthy Life Innovation Medical Technology Co., Ltd, with 512 participants planned, started 2022-12-20 and due to reach its primary completion in 2026-12-25. Interventions recorded: Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel and Gemcitabine hydrochloride and albumin binding paclitaxel.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.